Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pro-Pharma to get Federal Grants under QTDP program
The company said that the QTDP Program seeks to accelerate development of compounds that are novel and show great promise of success as treatments for disease. Pro-Pharmaceuticals has
The company said that the QTDP Program seeks to accelerate development of compounds that are novel and show great promise of success as treatments for disease. Pro-Pharmaceuticals has
Taliglucerase alfa is under review by the US Food and Drug Administration (FDA) with a Prescription Drug User Fee Action (PDUFA) date scheduled for 25 February 2011. The
Operating loss was $8.8m, compared to $7.09m for the comparable period in 2009. For the nine months ended 30 September 2010, Chelsea has posted a net loss of
As per the terms of the non-exclusive alliance, Dako and Quintiles will offer integrated drug-diagnostic development services and companion diagnostic products. The first such collaboration will support AstraZeneca
Depomed has posted a net income of $1.89m for the third quarter 2010, or $0.04 per diluted share, compared to $1.37m, or $0.03 per diluted share, for the
Heading up the center will be Bei Betty Zhang, a native of Shanghai and a diabetes expert who also serves as vice president of Research for Lilly Research
Pfizer posted a net income of $866m for the third quarter 2010, or $0.11 loss per diluted share, a decrease of 70%, compared to $2.88bn, or $0.43 loss
Teva posted a net income of $1.05bn for the third quarter 2010, or $1.15 per diluted share, compared to $649m, or $0.72 per diluted share, for the comparable
Reviewed by scientists at the Department of Health and Human Services, the research grant has been awarded to X-BODY for its human monoclonal antibody therapeutic project targeting metastatic
Depomed is a specialty pharmaceutical company with one product candidate through Phase 3 clinical development, another in Phase 3 clinical development, two approved products on the market and